TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers.…